Interfacial interactions of apolipoprotein AI and high density lipoprotein: Overlooked phenomena in blood‐material contact
Source abstract
Abstract
Abstract Apolipoprotein AI (apo AI) is the major protein component of high density lipoprotein (HDL), and represents ∼1% of the total protein content of plasma. In previous work, apo AI was identified as a major component of the protein layers adsorbed from plasma to biomaterials having a wide range of surface properties. Notwithstanding such indications of the major contribution of lipoprotein interactions, these phenomena have been largely overlooked in the blood‐contacting biomaterials area. In this communication, detailed quantitative data on the adsorption of apo AI to typical “biomedical” segmented polyurethane (PU) are reported. Using radiolabeled apo AI, adsorption levels from buffer and plasma were found to be ∼0.5 and ∼0.2 μg/cm2, respectively. Albumin adsorption from plasma was comparable at about ∼0.17 μg/cm2. Since, it is unknown how much of the adsorbed apo AI is associated with HDL versus how much is in the free state, the corresponding molar quantities cannot be determined with certainty. However, if it is assumed that all of the adsorbed apo AI is free, the molar quantities adsorbed from plasma were in the ratio apo AI:albumin = 2.77, compared with 0.00063 in plasma. Immunoblot data showed similar trends with respect both to the variation in adsorbed quantity with plasma concentration and to the relative adsorbed quantities of apo AI and albumin. These data show unequivocally the very strong surface activity of apo AI and suggest that a key future focus for blood compatibility research should be lipoprotein interactions. © 2011 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 99A: 109–115, 2011.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Blood properties and coagulation · Lipoproteins and Cardiovascular Health · Diabetes, Cardiovascular Risks, and Lipoproteins
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (51)
Show source-provided references
1. 10.1016/S0142-9612(02)00083-210.1016/S0142-9612(02)00083-2 ↗
2. 10.1016/j.cca.2007.10.02810.1016/j.cca.2007.10.028 ↗
3. 10.1677/JOE-08-023810.1677/JOE-08-0238 ↗
4. 10.1016/S1570-0232(02)00114-910.1016/S1570-0232(02)00114-9 ↗
5. 10.1074/mcp.M700090-MCP20010.1074/mcp.M700090-MCP200 ↗
6. 10.1186/ar144310.1186/ar1443 ↗
7. 10.1378/chest.07-164310.1378/chest.07-1643 ↗
8. Apos of human plasma high density lipoproteins. Biology, biochemistry and clinical significance
9. 10.1016/0006-291X(78)91614-510.1016/0006-291X(78)91614-5 ↗
10. 10.1093/nar/11.9.282710.1093/nar/11.9.2827 ↗
11. 10.1074/jbc.M109.09843410.1074/jbc.M109.098434 ↗
12. 10.1097/HCO.0b013e328304380610.1097/HCO.0b013e3283043806 ↗
13. 10.1161/01.ATV.0000194291.94269.5a10.1161/01.ATV.0000194291.94269.5a ↗
14. 10.1016/S0140-6736(01)07098-210.1016/S0140-6736(01)07098-2 ↗
15. 10.1016/S0140-6736(04)17018-910.1016/S0140-6736(04)17018-9 ↗
16. 10.1093/eurheartj/ehi00310.1093/eurheartj/ehi003 ↗
17. 10.1046/j.1365-2796.2003.01276.x10.1046/j.1365-2796.2003.01276.x ↗
18. 10.1001/jama.290.17.229210.1001/jama.290.17.2292 ↗
19. 10.1001/jama.290.17.232210.1001/jama.290.17.2322 ↗
20. Use of recombinant apos in vascular diseases: The case of apo AI
21. SemBioSys Genetics Incorporated (AB Canada) 2008. Access date: Dec 3 2009. Available at:http://www.sysbiosys.com.
22. Resverlogix Corporation (BC Canada) 2009. Access date: Dec 3 2009. Available at:http://www.resverlogix.com.
23. 10.1111/j.1749-6632.2002.tb04248.x10.1111/j.1749-6632.2002.tb04248.x ↗
24. 10.1097/01.CCM.0000171183.79525.6B10.1097/01.CCM.0000171183.79525.6B ↗
25. 10.1097/01.CCM.0000171272.50888.AD10.1097/01.CCM.0000171272.50888.AD ↗
26. 10.1016/0042-6822(90)90229-K10.1016/0042-6822(90)90229-K ↗
27. 10.1002/jcb.24045021410.1002/jcb.240450214 ↗
28. 10.1097/00002030-200305230-0000910.1097/00002030-200305230-00009 ↗
29. 10.1021/pr060323f10.1021/pr060323f ↗
30. 10.1172/JCI11481910.1172/JCI114819 ↗
31. 10.1002/jbm.82029030610.1002/jbm.820290306 ↗
32. 10.1016/j.biomaterials.2005.12.02510.1016/j.biomaterials.2005.12.025 ↗
33. 10.1055/s-0038-165342510.1055/s-0038-1653425 ↗
34. Pierce Chemical Company. Rockford IL USA. IODO‐GEN Iodination Reagent 1993.
35. Regoeczi E · 1984
36. 10.1016/j.colsurfb.2003.09.00410.1016/j.colsurfb.2003.09.004 ↗
37. 10.1097/00002480-200205000-0001710.1097/00002480-200205000-00017 ↗
38. 10.1016/S0142-9612(97)00242-110.1016/S0142-9612(97)00242-1 ↗
39. 10.1163/15685620232040193310.1163/156856202320401933 ↗
40. 10.1002/jbm.b.3032310.1002/jbm.b.30323 ↗
41. 10.1002/jbm.a.3097710.1002/jbm.a.30977 ↗
42. 10.1073/pnas.050687710310.1073/pnas.0506877103 ↗
43. 10.1002/jbm.a.3042410.1002/jbm.a.30424 ↗
44. CorneliusRM MacriJ BrashJL. Apo AI a major player in blood material interactions. Annual Meeting Society for Biomaterials San Antonio Texas;2009.
45. 10.1182/blood.V55.1.156.15610.1182/blood.V55.1.156.156 ↗
46. 10.1055/s-0038-166109310.1055/s-0038-1661093 ↗
47. 10.1002/jbm.a.3231910.1002/jbm.a.32319 ↗
48. 10.1016/0142-9612(92)90143-C10.1016/0142-9612(92)90143-C ↗
49. 10.1016/S0049-3848(01)00279-110.1016/S0049-3848(01)00279-1 ↗
50. 10.1111/j.1365-2796.2009.02074.x10.1111/j.1365-2796.2009.02074.x ↗
51. 10.1016/j.patbio.2004.07.01510.1016/j.patbio.2004.07.015 ↗